Pre-made Naxitamab benchmark antibody ( Whole mAb, anti-Ganglioside GD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-370

Pre-Made Naxitamab biosimilar, Whole Mab: Anti-Ganglioside GD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-370-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Naxitamab biosimilar, Whole Mab: Anti-Ganglioside GD2 therapeutic antibody
INN Name Naxitamab
TargetGanglioside GD2
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesMemorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics
Conditions ApprovedNeuroblastoma
Conditions ActiveOsteosarcoma
Conditions DiscontinuedBreast cancer;Sarcoma;Small cell lung cancer
Development Techna